Esperion Therapeutics ESPR Professional Service Fees Payable
Professional Service Fees Payable at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedProfessionalFeesCurrent.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's professional service fees payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's professional service fees payable?
- Esperion Therapeutics (ESPR) reported professional service fees payable of $3.02M in Q1 2026.
- How has Esperion Therapeutics's professional service fees payable changed year-over-year?
- Esperion Therapeutics's professional service fees payable decreased by 29.5% year-over-year, from $4.29M to $3.02M.
- What is the long-term trend for Esperion Therapeutics's professional service fees payable?
- Over 5 years (2020 to 2025), Esperion Therapeutics's professional service fees payable has grown at a 3.1% compound annual growth rate (CAGR), from $3.18M to $3.71M.
- What does professional service fees payable mean?
- This represents the outstanding balance owed to third-party providers for professional services such as consulting, auditing, or legal advisory. It is a component of current liabilities that reflects the company's short-term operational obligations. High levels may indicate significant reliance on external expertise or delays in payment cycles.